SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-18-205723
Filing Date
2018-06-27
Accepted
2018-06-27 16:11:36
Documents
4
Period of Report
2018-06-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d633682d8k.htm 8-K 39537
2 EX-3.1 d633682dex31.htm EX-3.1 5618
3 EX-4.1 d633682dex41.htm EX-4.1 79903
4 EX-10.1 d633682dex101.htm EX-10.1 119991
  Complete submission text file 0001193125-18-205723.txt   246803
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

IRS No.: 262774444 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 000-51122 | Film No.: 18921920
SIC: 3826 Laboratory Analytical Instruments
Assistant Director 10